The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
BackgroundThe association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison wi...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.646095/full |
id |
doaj-5094b808a226498fb602653e7bd9938c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Copaescu Ana Copaescu Ana Copaescu Fiona James Effie Mouhtouris Sara Vogrin Olivia C. Smibert Claire L. Gordon Claire L. Gordon George Drewett Natasha E. Holmes Natasha E. Holmes Natasha E. Holmes Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano |
spellingShingle |
Ana Copaescu Ana Copaescu Ana Copaescu Fiona James Effie Mouhtouris Sara Vogrin Olivia C. Smibert Claire L. Gordon Claire L. Gordon George Drewett Natasha E. Holmes Natasha E. Holmes Natasha E. Holmes Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study Frontiers in Immunology SARS-CoV-2 interleukin-6 C-reactive protein cytokine storm Staphylococcus aureus bacteraemia sepsis |
author_facet |
Ana Copaescu Ana Copaescu Ana Copaescu Fiona James Effie Mouhtouris Sara Vogrin Olivia C. Smibert Claire L. Gordon Claire L. Gordon George Drewett Natasha E. Holmes Natasha E. Holmes Natasha E. Holmes Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano Jason A. Trubiano |
author_sort |
Ana Copaescu |
title |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
title_short |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
title_full |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
title_fullStr |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
title_full_unstemmed |
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study |
title_sort |
role of immunological and clinical biomarkers to predict clinical covid-19 severity and response to therapy—a prospective longitudinal study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-03-01 |
description |
BackgroundThe association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined.MethodsA cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC).ResultsIL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity.ConclusionsKnowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs. |
topic |
SARS-CoV-2 interleukin-6 C-reactive protein cytokine storm Staphylococcus aureus bacteraemia sepsis |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.646095/full |
work_keys_str_mv |
AT anacopaescu theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT anacopaescu theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT anacopaescu theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT fionajames theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT effiemouhtouris theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT saravogrin theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT oliviacsmibert theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT clairelgordon theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT clairelgordon theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT georgedrewett theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT anacopaescu roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT anacopaescu roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT anacopaescu roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT fionajames roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT effiemouhtouris roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT saravogrin roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT oliviacsmibert roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT clairelgordon roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT clairelgordon roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT georgedrewett roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT natashaeholmes roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy AT jasonatrubiano roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy |
_version_ |
1724218755300458496 |
spelling |
doaj-5094b808a226498fb602653e7bd9938c2021-03-17T04:42:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-03-011210.3389/fimmu.2021.646095646095The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal StudyAna Copaescu0Ana Copaescu1Ana Copaescu2Fiona James3Effie Mouhtouris4Sara Vogrin5Olivia C. Smibert6Claire L. Gordon7Claire L. Gordon8George Drewett9Natasha E. Holmes10Natasha E. Holmes11Natasha E. Holmes12Jason A. Trubiano13Jason A. Trubiano14Jason A. Trubiano15Jason A. Trubiano16Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, AustraliaClinical Immunology and Allergy, Department of Medicine, McGill University Health Center, Montréal, QC, CanadaThe Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, CanadaCentre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, AustraliaCentre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, AustraliaDepartment of Medicine, St Vincent’s Hospital, University of Melbourne, Fitzroy, VIC, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC, AustraliaDepartment of Microbiology and Immunology, The University of Melbourne, Parkville, VIC, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC, AustraliaCentre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC, AustraliaDepartment of Critical Care, Melbourne Medical School, The University of Melbourne, Parkville, VIC, AustraliaCentre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC, AustraliaDepartment of Oncology, Sir Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC, AustraliaThe National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, VIC, AustraliaBackgroundThe association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined.MethodsA cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC).ResultsIL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity.ConclusionsKnowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs.https://www.frontiersin.org/articles/10.3389/fimmu.2021.646095/fullSARS-CoV-2interleukin-6C-reactive proteincytokine stormStaphylococcus aureus bacteraemiasepsis |